

Reporting, Causality assessment, Risk factors & Mechanisms of ADRs

Training Course, 26th - 27th May 2011, Minsk, Belarus

Belarusian Medical Academy of Post-Graduate Education 3, Brovki str., build.3, 220013, Minsk, Republic of Belarus

Enguiries: ISoP Phone and Fax +44 (0)20 3256 0027 www.isoponline.org administration@isoponline.org

This basic two day-seminar will be dedicated to introduce HCP to the concepts of pharmacovigilance and drug safety, and to understand better the basics of pharmacovigilance, centred on the individual case reports (the patient), the identification of drug-related risks, and their management at the patient level.

Day 1: Thursday 26th May 2011 ADR evaluation and ADR reporting

Chairpersons: Hervé Le Louet & Svetlana Setkina

8.30 to 9.00 am Registration

9.00 - 9.15 am **Introduction - Course objectives** Hervé Le Louet, ISoP

9.15 - 9.55 am

Epidemiology and identification of adverse drug reactions

Alexander Dodoo, ISoP

9.55 - 10.40 am

Adverse drug reactions: mechanism and classification

Raquel Herrera Comoglio, School of Medicine, Córdoba National University, Argentina

10.40 - 11.00 am Adverse drug reactions terminology Alexander Dodoo, ISoP

11.00 – 11.30 am Coffee-break

11.30 - 12.15

Causality assessment in individual case

Raquel Herrera Comoglio, School of Medicine, Córdoba National University, Argentina

1

12.15 to 1.00 pm

Causality assessment in case series

Richard Hill, Uppsala Monitoring Centre, Sweden

<u>Lunch</u>: 1.00 – 2.00 pm

2.00 - 2.40 pm

Causality assessment in hepatotoxicity and dermatotoxicity

Hervé Le Louet, ISoP

2.40 - 3.00 pm

Causality assessment in gastrotoxicity

Larisa Gavrilenko, Clinical Pharmacology, Belorusian State Medicinal University, Minsk, Belarus

3.00 - 3.20 pm

Causality assessment in nephrotoxicity

Marina Sachek, Republican Scientific and Practical Center for Medical Technologies, Informatization, Administration and Management of Health, Minsk, Belarus

3.20 - 3.40 pm

Causality assessment in immunotoxicity

Eduard Docenko, Medical Faculty for International Students of the Belorusian State Medicinal University, Minsk, Belarus

3.40 - 4.00 pm

Coffee-break

4.00 – 4.35 pm

Reporting recommendations (international, EU and national)

Ulrich Hagemann, ISoP

4.35 – 5.00 pm

International Reporting - The WHO programme

Marie Lindquist, ISoP

5.00 – 5.20 pm

Averse drug reactions reporting form: essential information

Alexander Dodoo, ISoP

5.20 - 5.30 pm

Closing remarks

Day 2: Friday 27th May 2011 ADR monitoring and risk minimization activity

Chairpersons: Hervé Le Louet & Svetlana Setkina

Welcome to Day 2

8.45 - 9.25 am

Drug therapy in various pharmacokinetics-modifying disorders

Andryan Najaran, Republican Clinical Pharmacological Laboratory of the Centre for Examinations and Tests in Health Service, Minsk, Belarus

9.25 - 9.55 am

Early signs of drug toxicity

Eugène van Puijenbroek, ISoP

9.55 - 10.25 am

Age factors in drug therapy

Eugène van Puijenbroek, ISoP

10.25 - 11.00 am

Clinically significant drug interactions

Richard Hill, Uppsala Monitoring Centre, Sweden

11.00 – 11.30 am

Coffee-break

11.30 - 12.00

Pharmacogenetic approach in understanding and preventing adverse drug reactions

Raquel Herrera Comoglio, School of Medicine, Córdoba National University, Argentina

12.00 - 12.40

Approaches to the individual benefit-risk assessment in high-risk groups

Dzmitry Razdzestvensky, Republican Clinical Pharmacological Laboratory of the Center for Examinations and Tests in Health Service, Minsk, Belarus

12.40 - 1.00 pm

Medication errors: definition and measures to avoid

Ulrich Hagemann, ISoP

1.00 to 2.00 pm

Lunch

2.00 - 2.30pm

Generics, similars and bioequivalence

Luis Alesso, ISoP

2.30 - 3.00

How to deal with lack of effectiveness' pharmacovigilance reports Luis Alesso, ISoP

3.00 to 3.30 pm Coffee-break

3.30 to 4.15

Challenges in establishing a local pharmacovigilance

Svetlana Setkina, Center for Examinations and Testing in Health Service of the Republic of Belarus

4.15 – 4.30 pm Closing remarks

The International Society of Pharmacovigilance gratefully acknowledges assistance from the Center for Examinations and Testing in Health Service of the Republic of Belarus as partner co-organizer